2022-04-06

Camurus Annual Report for 2021

Lab Work

Camurus Annual Report for 2021 is now available at the company's website.

“2021 was a productive and successful year for Camurus where we, under challenging market conditions, continued to advance our business towards our strategic goals. Revenues grew by high double digits and the operating result continued to improve whilst we made significant investments in our pipeline of innovative medicines. We received new and extended regulatory approvals for Buvidal® for the treatment of opioid dependence and advanced key development programs towards the market”, says Fredrik Tiberg, President and CEO of Camurus.

The annual report can be found at Camurus' website: www.camurus.com.

Latest news

2018-07-19

Sandberg Development invests in water technology company SWATAB

The family owned investment company Sandberg Development invests in SWATAB (SCANDINAVIAN WATER TECHNOLOGY AB). The i…

Read more

2018-06-29

We have updated our privacy policy

On the 25th of May 2018 the new regulation in EU law on data protection and privacy for all individuals within the E…

Read more

2018-01-31

Sandberg Development invests in Orbital Systems

Sandberg Development invests SEK 30 million in the Malmö-based water recycling technology Company Orbital Systems.

Read more

2017-09-18

Sandberg Development invests in new development company

As part of our business concept - "Investing in innovations with growth in focus" - Sandberg Development has, during…

Read more

2017-05-19

Camurus and Braeburn Pharmaceuticals announce positive Top-line results from long-term Phase 3 safety study of CAM2038

New data support long-term safety and efficacy of weekly and monthly subcutaneous buprenorphine depots in patients w…

Read more